Andrea Park

Andrea Park, a skilled reporter, has extensively covered the evolving field of immunotherapy in endometrial cancer. She wrote an insightful article titled ‘AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain,’ where she discussed the latest developments and ongoing clinical trials involving major pharmaceutical companies. Park reported on GSK’s Jemperli regimens, which are being explored for a broader patient demographic in endometrial cancer, and AstraZeneca’s similar strategies awaiting FDA decisions. She highlighted the results from GSK’s Jemperli combined with chemotherapy, showing a significant reduction in death risk among patients with advanced endometrial cancer. Additionally, she covered the exploratory analysis of the phase 3 RUBY trial presented at the Society of Gynecologic Oncology annual meeting and noted GSK’s expectations for FDA approval to expand Jemperli’s use in front-line endometrial cancer treatment. Park also discussed concerns regarding the long-term effects of PARP inhibitors and reported on AstraZeneca’s promising DUO-E trial results, which demonstrated a substantial decrease in mortality risk when combining Imfinzi, Lynparza, and chemotherapy. Her reports also mentioned that AstraZeneca’s filings for the DUO-E trial had been accepted by multiple regulatory bodies, including the FDA, the European Medicines Agency, and Japanese regulators.